(Total Views: 1051)
Posted On: 03/01/2022 5:32:59 PM
Post# of 154134
Okay, I'll post again.
The longer we go without hearing what's up with the money we owe Samsung, the greater the chances our negotiations involve them.
Also...
All this talk about a buyout at $10 or less, in my humble opinion, is worthless. Cytodyn is not in a position where they have to take any buyout offer on the table to stay afloat. They can sell shares, they can license LL out in a variety of ways. The people who are on the team are there because they believe in the potential of Leronlimab. If we were out of options, sure, maybe that's just what they'd have to do. But the current problem is cash and there are multiple ways to get cash right now.
A buyout offer above that is a different story, but I just don't think that's what's going on any longer. I'm adjusting my predictions as we sit around longer. Now it's going to be:
Samsung in the Asian Market with the Nash/Cancer License.
The longer we go without hearing what's up with the money we owe Samsung, the greater the chances our negotiations involve them.
Also...
All this talk about a buyout at $10 or less, in my humble opinion, is worthless. Cytodyn is not in a position where they have to take any buyout offer on the table to stay afloat. They can sell shares, they can license LL out in a variety of ways. The people who are on the team are there because they believe in the potential of Leronlimab. If we were out of options, sure, maybe that's just what they'd have to do. But the current problem is cash and there are multiple ways to get cash right now.
A buyout offer above that is a different story, but I just don't think that's what's going on any longer. I'm adjusting my predictions as we sit around longer. Now it's going to be:
Samsung in the Asian Market with the Nash/Cancer License.
(15)
(0)
